In this study we also used a murine colon cancer model to determine what factors affected immune checkpoint inhibitor blockade, and, even though the vaccine vectors used were different, we observed that tumors were smaller in mice treated with pVAX-α-PD-1 than in those in the pVAX-empty vector group 15 days after tumor inoculation, which means that pVAX-α-PD-1 monotherapy can suppress tumor growth. Here, RPL17 is linked to malignant colon neoplasm.